Revised MRP List Slashes Prices of Cancer Drugs by Up to 93%
Health activists express concerns over drastic price cuts in cancer medications, highlighting issues of affordability and excessive pricing.
The NPPA has revised prices of 543 anti-cancer medicines effective November 9, 2026.
Significant price reductions raise questions about pharmaceutical pricing practices.
Experts call for comprehensive reforms beyond mere price caps to ensure drug affordability.
On October 28, 2026, the National Pharmaceutical Pricing Authority (NPPA) announced a revised Maximum Retail Price (MRP) list for anti-cancer medications, revealing drastic price cuts of up to 93% for several drugs. This list, which includes 543 brands, will take effect on November 9, raising alarms among health activists regarding the longstanding issue of excessive pricing in the pharmaceutical industry.
The NPPA's announcement follows a previous directive on October 17, where the authority introduced Trade Margin Rationalisation (TMR) for 137 non-scheduled anti-cancer drugs. This initiative aims to reduce excessive trade margins and enhance the affordability of cancer treatments. The revised MRP reflects data submitted by manufacturers up to October 27, 2026, with the NPPA indicating that updates will continue as companies report new prices.
Among the notable price changes, the cost of palbociclib plummeted from approximately ₹40,421 to ₹2,720 per pack, while thiotepa saw a reduction from ₹80,072 to ₹7,150 per vial. Such significant drops have prompted scrutiny of the pricing strategies employed by pharmaceutical companies, particularly those producing generic cancer medications. Despite these reductions, many patented cancer drugs remain prohibitively expensive, raising concerns about the effectiveness of the TMR policy in ensuring affordability.
Health organizations, including Jan Swasthya Abhiyan India (JSA India), argue that merely controlling trade margins is insufficient. They emphasize the need for a cost-based pricing approach to further lower drug prices and prevent profiteering. Experts warn that high drug costs can lead to treatment delays or discontinuation, adversely affecting patient outcomes. Dr. Tanvi Singh, a medical oncologist, highlighted the necessity of lowering drug costs to improve treatment continuity and reduce financial burdens on patients.
Looking ahead, stakeholders urge the NPPA to enhance its oversight of price data collection and verification processes. They advocate for a comprehensive strategy that includes expanding insurance coverage, increasing access to quality generics, and bolstering Patient Assistance Programs. The recent price control measures are viewed as a positive step, but experts stress that sustainable solutions are needed to ensure that life-saving medications remain accessible and affordable for all patients.
